Press Release

Winner of ICI Innovation Award 2013 Announced

EMBARGOED UNTIL 1030am
Tuesday 3rd December 2013

Tel Aviv, Israel… Today in Tel Aviv, the winner of the ICI Innovation Awards Best Business Start-Up Award for 2013 was announced in front of an audience of 1200 international cardiologists.

The winner is a US company, Clear Catheter Systems Inc., for their device Active Clearance Technology® to improve the outcomes of patients undergoing open heart surgery.
After chest surgery, surgeons place tubes through the chest wall which allow blood and other fluids to drain away. A common problem occurring in more than a third of patients, is where the tubes block and cause increased pressure inside the chest, potentially compromising the heart and lungs and meaning that the patient may need to return to theatre for a second operation.

PleuraFlow® Active Clearance Technology® enables caregivers to actively keep chest tubes clear of clot through the use of a patented technology utilising special magnets and movable shaped wires.

The innovation, developed by heart surgeons, is approved by the FDA and has the potential to reduce the number of emergency revision procedures, create significant cost savings to hospitals, and most importantly, save lives.

"We are honoured to have won this prestigious Award, judged by some of the world's foremost experts in the field" said Founder Edward Boyle. "*This will help increase our visibility to the clinical world and speed up adoption of this important technology to improve patient care".*

Chairman of the Judging Panel, Professor Martin Rothman stated, *"The Judges were enthused by the wealth of innovation and entrepreneurship displayed by the shortlisted candidates. The winner was selected because of its simplicity, clear potential to have clinical impact and business opportunity".*

This Award was sponsored by Medtronic Inc through an unrestricted grant.

About Clear Catheter Systems Inc.

Clear Catheter Systems, a spinout from collaboration between MDI Partners (a medical device incubator) and the Cleveland Clinic Foundation, is a Bend, Oregon based privately held medical device company pioneering new technologies to solve the clinical problems associated with obstructed catheters. The company has a pipeline of products based on its proprietary tube clearance technologies to resolve catheter clogging in other medical market segments, including urinary catheters, gastrointestinal catheters, and wound drainage.

Contacts

Name: Amy Gibson
Tel: 001 925 699 4407
Email: amy@bloomcreative.com
Location: USA

www.pleuraflow.com

About the ICI Innovation Best Start-Up Innovation Award

The ICI Innovation Awards is the world's largest and most prestigious award for cardiovascular start-ups.

The ICI Innovation Award offers cardiovascular Start-Up's the opportunity to obtain critical peer review and feedback from a world class panel of clinical and commercial experts. Entrants are invited to pitch their idea face to face to the Who's Who panel of experts who then quiz them on the clinical and commercial opportunity. The panel of Judges determine the winner based on three principal criteria: The impact on novelty; impact on patient care; and business potential.

Winning an ICI Innovation Award offers unparalleled clinical and commercial validation. The winner is offered assistance, guidance and contacts towards investment with the expressed aim of driving the idea towards benefitting patients. Winners also are offered the opportunity to present their innovation to thousands of doctors both at the ICI Meeting in Israel, as well as at Europe's largest cardiovascular meeting, EuroPCR in May 2014. International finalists also receive financial support towards registration fees and hotel accommodation and the winner has their travel reimbursed.

The ICI Innovation Awards are run in association with the "Innovations in Cardiovascular Interventions" (ICI) Meeting which takes place in December in Tel Aviv in Israel (see www.icimeeting.com)

The competition is in its third year, and each year more than 70 applications from 22 countries around the world enter and are whittled down to a shortlist of just 10 who are invited to present. The award is sponsored by Medtronic Inc through an unrestricted grant.

Entries for the 2014 ICI Innovation Awards are now open.

For further details on the Award Judges please see http://ici.medicalfutures.co.uk

Contact: Martine Morris
Email: martine@medicalfutures.co.uk **Telephone:** +44(0)7939 801 100

Commendation and shortlist

Two Companies received special commendations by the Judges as Runners-Up in the Competition. These are listed below:

Embo Medical

Title: The Caterpillar

Embo Medical has developed innovative medical device technology to treat diseased, peripheral vascular vessels and organs. The company has produced the first one-shot peripheral vascular embolization device, the Caterpillar; a unique platform technology for use in the field of embolization; a minimally invasive procedure to deliberately and permanently stop blood flow in a blood vessel. The Embo platform technology provides a superior solution in shorter procedural times; resulting in safe, cost-effective embolization. The Company's objective is to bring to market the Caterpillar and prove its clinical and commercial validity.

Contacts

Name: Wayne Allen
Tel: +(353) 87 67 65829
Email: wayneallen@embomedical.com
Location: Republic Ireland

www.embomedical.com

ControlRad Systems

Title: Radiation Dose Reduction in Interventional Medicine

ControlRad Systems is a medical device company developing products that aims to dramatically reduce radiation dose to patients and physicians performing the procedure.

Interventional heart procedures expose medical staff and patients to ionizing radiation, more than any other x-ray procedure and the company are developing a novel solution that uses eye-tracking technology to track the gaze of the physician in real-time, enabling a dynamic collimator to instantly provide full dose radiation in the region of interest and substantially lower doses of radiation to the peripheral field of view.

By delivering the right amount of radiation to the right spot at the right time, dramatic dose reductions (typically 80%) have been achieved with no loss of image quality inside the region of interest and acceptable image quality in the periphery and most importantly, there has been no change to existing physician workflow.

Contacts

Name: Dr Allon Guez
Tel: +(1) 215 470 2300
Email:guez@controlradsystems.com
Location: USA

www.controlradsystems.com

The Final Innovation shortlist also included:

Cardiologic Innovations

Title: Game changing pulmonary congestion and respiratory parameters monitoring technology

CardioLogic breakthrough pEIT™ technology is the basis for non-invasive pulmonary congestion and respiratory parameters monitoring, for many medical conditions, including among others: heart failure, acute myocardial infraction, ARDS, septic shock, and end stage renal disease.

The pEIT™ technology can calculate separately in each lung near absolute fluid levels independent of the patient, and is highly sensitive to small lung fluid changes, as demonstrated in pre-clinical and clinical feasibility studies.

It is the basis for a single Lung Fluid Index LFi™ across various non- invasive and implantable devices through the continuum of care.

Contacts

Name: Danny Weiss
Tel: +(972) 544 854 520
Email: danny.weiss1@gmail.com
Location: Israel

www.cardiologic-innovations.com

NI Medical

Title: Non Invasive Cardiac System

NI*Medical*, an Israeli based medical device Company, have developed the whole body bioimpedance technology focusing on noninvasive assessment and monitoring of cardiovascular patients. The company's first generation product, the NICaS, is a Laptop based medical device designed for Hospitals, Outpatient Facilities, and Home Healthcare programs. The NICaS was launched in 2012 with about $400,000 of customers' sales in its first year and $4 million of customer's commitments.

The company's next generation product in development, is designed as a Smartphone application to be used at home by the patient as a telemedicine device, transmitting physiological data to the physician for evaluation. This would be revolutionary in the management of cardiovascular patients resulting in significant reduction of hospital's admission rates, savings to the healthcare system and aiming to improve patients' quality of life.

Contacts

Name: Adi Livneh
Tel: +(972) 526 148 800
Email: alivneh@nimedical.co.il
Location: Israel

www.nimedical.co.il

HEADSENSE

Title: Non-invasive ICP monitor

HeadSense Medical Ltd is an early stage company, developing a non-invasive intracranial pressure (ICP) monitor. HeadSense is extending the availability of ICP monitoring to medical areas that cannot measure ICP currently, due to the invasive nature of the current procedure.

HeadSense is developing an innovative device, based on advanced signal analysis. The device generates an acoustic signal that is transmitted using a small headset-like microphone, placed in the patient's ear, and picked by an acoustic sensor placed in the other ear. The signal is then analyzed using proprietary algorithms, and the ICP value is displayed to the user. The device is disposable, and it is capable of performing continuous monitoring of ICP and provides quantitative data in pressure units (mmHg). In addition to ICP monitoring, the technology shows promising potential in measuring other neurological and cardiac parameters. In the future, it will be possible to provide a complete diagnosis of the patient's neurological respiratory and cardiac condition.

Contacts

Name: Guy Weinberg
Tel: +(972) 544 809 445
Email: guy@head-sense-med.com
Location: Israel

www.head-sense-med.com

AUM Cardio

Title: CADence: Noninvasive, Fast Detection of Obstructive Coronary Disease

AUM Cardiovascular, Inc. is a Northfield Minnesota based medical device start-up developing a non-invasive device capable of detecting obstructive coronary artery disease. Using high fidelity sensors, the CADence™ detects acoustic information caused by turbulence within the coronary vessel. With a heuristic model, CADence™ extracts subtle information while making allowance for physiological and anatomical differences experienced in clinical medicine. The CADence™ is comprised of a handheld, RFID-tagged booklet and remote algorithm, which in combination keeps patient information secure and diagnoses fast and reliable. The device is user-friendly and the results are available within minutes.
CADence™ is currently in U.S. FDA pivotal trial proving non-inferiority to nuclear stress test.

Contacts

Name: Paige Kraus
Tel: +(1) 952-200-0061
Email: paige@aumcardiovascular.com
Location: USA

www.aumcardio.com

Graft Solutions

Title: Venous External Scaffolding Technology (VEST)

Vein graft failure following Coronary Artery Bypass Grafting (CABG) is a major limitation which may lead to re-interventions. The underlying pathology of vein graft failure is intimal hyperplasia which is is triggered by low shear stress and high wall tension and lead to accelerated atherosclerosis. VGS developed the VEST, a CE marked, Venous External Scaffolding Technology for vein grafts. A randomized controlled, multi- center study in Europe demonstrated the VEST's effectiveness in mitigating intimal hyperplasia and increasing vein graft performance by preventing vein graft's dilatation, eliminating vein graft's lumen irregularities and flow disturbances and limiting the vein graft's wall tension.

Contacts

Name: Dr Eyal Orion
Tel: +(972) 354 990 54

Email: eyal@graftsolutions.com

Location: Israel

www.graftsolutions.com

EDIXOMED LTD

Title: ProNOx: ReDressing the Nitric Oxide Balance in Vascular Disease

EdixoMed Limited (EdixoMed) is a clinical stage biopharmaceutical company, based in Scotland, developing a novel, proprietary nitric oxide (NOx) generating technology that has broad clinical application. EdixoMed's initial focus is on two specific therapeutic franchises: a wound care division; and a respiratory division.

Edixomed's primary innovation is a nitric oxide (NOx)-generating platform technology, with great potential in many therapeutic areas. First invented at Queen Mary University of London and St Bartholomew's Hospital, the technology was latterly licensed to Edixomed Ltd. The lead product is a NOx-generating wound dressing, recently entered into Phase II clinical evaluation. The elegant 2-part system comprises a non-adherent "mesh" under layer, containing nitrite, and a proprietary Hydrogel layer, which on contact release exogenous NOx into the target tissues. The system harnesses the natural roles of nitric oxide: regulating vascular resistance, blood flow, platelet aggregation, and potent broad-spectrum antimicrobial properties.

Contacts

Name: Dr Joanne Stewart
Mr Carl Daintree

Email: joanneejames@gmail.com
carldaintree@edixomed.com

Tel: +(44) 7540 162 962

Location: UK

www.edixomed.com

DHS Medical

Title: Twistek Heart motion based real-time continuous optimization of CRT

DHS Medical aims to improve quality of life of patients with heart failure. As almost all CRM systems use electric heart signals as input, we at DHS Medical focus on heart motion signals. We are confident that heart motion signals will improve mechanical synchronization between heart chambers. DHS Medical develops Twistek technology which measures heart motion signals using accelerometers and gyroscopes incorporated into standard implantable leads. Real-time, continuous analysis of motion signals provides input for optimized cardiac resynchronization. Twistek technology underlies our next generation Cardiac Resynchronization Therapy system.

Contacts

Name: Dr Guy Dori
Tel: +(972) 506 265 516
Email: guydori2512@gmail.com
Location: Israel

www.dhsmedical.com

ENDS